Turna Ray

Researchers analyzed molecular and particulate matter exposure data on nearly 9,000 NSCLC patients in France and confirmed a link reported by UK scientists in 2022.

A new CPT code may better account for the work genetic counselors do, but will it be used more and lead to reimbursement that sustains the profession?

A study drawing on germline genetic testing and claims data showed at ASCO that patients with VUS are, for the most part, managed like they have negative results.

In UK Biobank data, researchers found that clonal hematopoiesis of indeterminate potential exacerbates the impact of air pollution in non-smokers with lung cancer.

At AACR's annual meeting, industry observers discussed how FDA's stance on RUOs amid its push to regulate LDTs is putting the "double squeeze" on the lab industry.

At ASH, researchers reported that a PGx-based score could identify the cytarabine-based induction therapy young Black patients are most likely to benefit from.

Laws passed in 14 states appear to require commercial payors to cover biomarker tests broadly that meet certain evidentiary criteria, but payors may have a different interpretation.

Alternative clinical decision support services are available, industry observers said, but it's not clear whether they, too, will be subject to FDA enforcement.

The firm was pursing 510(k) clearance for software that provides treatment recommendations based on PGx variants detected by lab customers, but the FDA issued a negative decision.

The projects signal ongoing concern among health regulators about the quality and regulation of lab-developed tests used to guide cancer treatment and gauge disease risk.